Literature DB >> 29196338

Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.

Rupert L Mayer1, Josef D Schwarzmeier2, Marlene C Gerner3, Andrea Bileck1, Johanna C Mader1, Samuel M Meier-Menches1, Samuel M Gerner1, Klaus G Schmetterer3, Tobias Pukrop4, Albrecht Reichle4, Astrid Slany1, Christopher Gerner5,6.   

Abstract

B cell chronic lymphocytic leukemia (B-CLL), the most common type of leukemia in adults, is still essentially incurable despite the development of novel therapeutic strategies. This reflects the incomplete understanding of the pathophysiology of this disease. A comprehensive proteome analysis of primary human B-CLL cells and B cells from younger as well as elderly healthy donors was performed. For comparison, the chronic B cell leukemia cell line JVM-13 was also included. A principal component analysis comprising 6,945 proteins separated these four groups, placing B cells of aged-matched controls between those of young donors and B-CLL patients, while identifying JVM-13 as poorly related cells. Mass spectrometric proteomics data have been made fully accessible via ProteomeXchange with identifier PXD006570-PXD006572, PXD006576, PXD006578, and PXD006589-PXD006591. Remarkably, B cells from aged controls displayed significant regulation of proteins related to stress management in mitochondria and ROS stress such as DLAT, FIS1, and NDUFAB1, and DNA repair, including RAD9A, MGMT, and XPA. ROS levels were indeed found significantly increased in B cells but not in T cells or monocytes from aged individuals. These alterations may be relevant for tumorigenesis and were observed similarly in B-CLL cells. In B-CLL cells, some remarkable unique features like the loss of tumor suppressor molecules PNN and JARID2, the stress-related serotonin transporter SLC6A4, and high expression of ZNF207, CCDC88A, PIGR and ID3, otherwise associated with stem cell phenotype, were determined. Alterations of metabolic enzymes were another outstanding feature in comparison to normal B cells, indicating increased beta-oxidation of fatty acids and increased consumption of glutamine. Targeted metabolomics assays corroborated these results. The present findings identify a potential proteome signature for immune senescence in addition to previously unrecognized features of B-CLL cells and suggest that aging may be accompanied by cellular reprogramming functionally relevant for predisposing B cells to transform to B-CLL cells.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29196338      PMCID: PMC5795392          DOI: 10.1074/mcp.RA117.000425

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  94 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.

Authors:  Chang-Liang Su; Tao-Ran Deng; Zhen Shang; Yi Xiao
Journal:  Int J Hematol       Date:  2015-05-05       Impact factor: 2.490

3.  Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma.

Authors:  Peter Ugocsai; Daniel Wolff; Karin Menhart; Dirk Hellwig; Ernst Holler; Wolfgang Herr; Albrecht Reichle
Journal:  Br J Haematol       Date:  2015-05-05       Impact factor: 6.998

4.  Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer.

Authors:  Anna Bachmayr-Heyda; Stefanie Aust; Katharina Auer; Samuel M Meier; Klaus G Schmetterer; Sabine Dekan; Christopher Gerner; Dietmar Pils
Journal:  Clin Cancer Res       Date:  2016-10-19       Impact factor: 12.531

Review 5.  Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases.

Authors:  Nard Kubben; Tom Misteli
Journal:  Nat Rev Mol Cell Biol       Date:  2017-08-09       Impact factor: 94.444

Review 6.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 7.  Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities.

Authors:  Ciaran O'Reilly; Mohammad Doroudian; Leona Mawhinney; Seamas C Donnelly
Journal:  Med Res Rev       Date:  2016-01-18       Impact factor: 12.944

Review 8.  Sugar and fat - that's where it's at: metabolic changes in tumors.

Authors:  Christian D Young; Steven M Anderson
Journal:  Breast Cancer Res       Date:  2008-02-20       Impact factor: 6.466

9.  Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.

Authors:  Christina Hart; Martin Vogelhuber; Daniel Wolff; Sebastian Klobuch; Lina Ghibelli; Jürgen Foell; Selim Corbacioglu; Klaus Rehe; Guy Haegeman; Simone Thomas; Wolfgang Herr; Albrecht Reichle
Journal:  Cancer Microenviron       Date:  2015-08-11

10.  An age-related numerical and functional deficit in CD19(+) CD24(hi) CD38(hi) B cells is associated with an increase in systemic autoimmunity.

Authors:  Niharika A Duggal; Jane Upton; Anna C Phillips; Elizabeth Sapey; Janet M Lord
Journal:  Aging Cell       Date:  2013-07-19       Impact factor: 9.304

View more
  24 in total

Review 1.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

2.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

Review 3.  Deciphering Metabolic Adaptability of Leukemic Stem Cells.

Authors:  Sweta B Patel; Travis Nemkov; Angelo D'Alessandro; Robert S Welner
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

4.  Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.

Authors:  Sophie A Herbst; Mattias Vesterlund; Alexander J Helmboldt; Rozbeh Jafari; Ioannis Siavelis; Matthias Stahl; Eva C Schitter; Nora Liebers; Berit J Brinkmann; Felix Czernilofsky; Tobias Roider; Peter-Martin Bruch; Murat Iskar; Adam Kittai; Ying Huang; Junyan Lu; Sarah Richter; Georgios Mermelekas; Husen Muhammad Umer; Mareike Knoll; Carolin Kolb; Angela Lenze; Xiaofang Cao; Cecilia Österholm; Linus Wahnschaffe; Carmen Herling; Sebastian Scheinost; Matthias Ganzinger; Larry Mansouri; Katharina Kriegsmann; Mark Kriegsmann; Simon Anders; Marc Zapatka; Giovanni Del Poeta; Antonella Zucchetto; Riccardo Bomben; Valter Gattei; Peter Dreger; Jennifer Woyach; Marco Herling; Carsten Müller-Tidow; Richard Rosenquist; Stephan Stilgenbauer; Thorsten Zenz; Wolfgang Huber; Eugen Tausch; Janne Lehtiö; Sascha Dietrich
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

Review 5.  Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.

Authors:  Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Simone Thomas; Tobias Pukrop; Christina Hackl; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

6.  Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.

Authors:  Gabriela Galicia-Vázquez; Raquel Aloyz
Journal:  Front Oncol       Date:  2018-09-26       Impact factor: 6.244

7.  Proteome Analysis Reveals Distinct Mitochondrial Functions Linked to Interferon Response Patterns in Activated CD4+ and CD8+ T Cells.

Authors:  Marlene C Gerner; Laura Niederstaetter; Liesa Ziegler; Andrea Bileck; Astrid Slany; Lukas Janker; Ralf L J Schmidt; Christopher Gerner; Giorgia Del Favero; Klaus G Schmetterer
Journal:  Front Pharmacol       Date:  2019-07-10       Impact factor: 5.810

8.  The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).

Authors:  Weilu Kuang; Wuzhong Jiang; Yinyun Chen; Yifu Tian; Zhengzheng Liu
Journal:  Cancer Biol Ther       Date:  2021-07-12       Impact factor: 4.875

9.  Structural Similarity with Cholesterol Reveals Crucial Insights into Mechanisms Sustaining the Immunomodulatory Activity of the Mycotoxin Alternariol.

Authors:  Giorgia Del Favero; Raphaela M Mayer; Luca Dellafiora; Lukas Janker; Laura Niederstaetter; Chiara Dall'Asta; Christopher Gerner; Doris Marko
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

10.  Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.

Authors:  Simar Pal Singh; Marjolein J W de Bruijn; Mariana P de Almeida; Ruud W J Meijers; Lars Nitschke; Anton W Langerak; Saravanan Y Pillai; Ralph Stadhouders; Rudi W Hendriks
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.